Overview of ‘omics technologies for military occupational health surveillance and medicine

Military Medicine

Volumn 180, Issue 10, 2015, Pages 34-48

  Bradburne, Christopher ^a   Graham, David ^b   Kingston, H M ^c   Brenner, Ruth ^d   Pamuku, Matt ^e   Carruth, Lucy ^a  

^a JOHNS HOPKINS UNIVERSITY APPLIED PHYSICS LABORATORY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUQUESNE UNIVERSITY   (United States)

^d Air Force Medical Support Agency USAF SG   (United States)

^e Applied Isotope Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DANGEROUS GOODS;

BLOOD; DANGEROUS GOODS; GENE EXPRESSION PROFILING; GENOMICS; HEALTH SURVEY; HUMAN; IMMUNITY; METABOLOMICS; OCCUPATIONAL EXPOSURE; PROCEDURES; SOLDIER; SPECIMEN HANDLING; STANDARDS;

BIOMARKERS; GENE EXPRESSION PROFILING; GENOMICS; HAZARDOUS SUBSTANCES; HUMANS; IMMUNE SYSTEM PHENOMENA; METABOLOMICS; MILITARY PERSONNEL; OCCUPATIONAL EXPOSURE; PUBLIC HEALTH SURVEILLANCE; SPECIMEN HANDLING;

EID: 84943552914     PISSN: 00264075     EISSN: 1930613X     Source Type: Journal    
DOI: 10.7205/MILMED-D-15-00050     Document Type: Article

References (75)

1. Vlaanderen J, Moore LE, Smith MT, et al: Application of OMICS technologies in occupational and environmental health research; current status and projections. J Occup Env Med 2010; 67(2): 136–43.
2. Rappaport SM, Smith MT: Epidemiology. Environment and disease risks. Science 2010; 330: 460–1.
3. Vrijheid M, Slama R, Robinson O, et al: The human early-life exposome (HELIX): project rationale and design. Environ Health Perspect 2014; 122(6): 535–44.
4. Centers for Disease control: Exposome and exposomocs. Available at ; accessed December 23, 2014.
5. Environmental Protection Agency: Investigating the human exposome. Available at ; accessed December 23, 2014.
6. Mill J, Petronis A: Molecular studies of major depressive disorder: the epigenetic perspective. Mol Psychiatry 2007; 12: 799–814.
7. Otto M, Bowser R, Turner M, et al: Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler 2012; 13(1): 1–10.
8. Marko-Varga G: BioBanking as the central tool for translational medicine CTM issue 2013. Clin Transl Med 2013; 2: 4.
9. Timmerman P, White S, Cobb Z, et al: Update of the EBF recommendation for the use of DBS in regulated bioanalysis integrating the conclusions from the EBF DBS-microsampling consortium. Bioanalysis 2013; 5: 2129–36.
10. Vékey K, Telekes A, Vertes A: Medical Applications of Mass Spectrometry, Ed 1, Oxford, United Kingdom, Elsevier Publishers, 2008.
11. Chambers AG, Percy AJ, Yang J, Camenzind AG, Borchers CH: Multiplexed quantitation of endogenous proteins in dried blood spots by multiple reaction monitoring-mass spectrometry. Mol Cell Proteomics 2013; 12: 781–91.
12. Fairwell T, Barnes WT, Richards FF, Lovins RE: Sequence analysis of complex protein mixtures by isotope dilution and mass spectrometry. Biochemistry 1970; 9: 2260–7.
13. EPA Publication SW-846: Test methods for evaluating solid waste, physical/chemical methods: method 6800, elemental and molecular speciated isotope dilution mass spectrometry, Update V. (2007). Available at http://www.epa.gov/osw/hazard/testmethods/sw846/pdfs/6800.pdf; accessed January 5, 2015.
14. Landrigan PJ, Lambertini L, Birnbaum LS: A research strategy to discover the environmental causes of autism and neurodevelopmental disabilities. Environ Health Persp 2012; 120: a258–60.
15. Roberts RJ, Carneiro MO, Schatz MC: The advantages of SMRT sequencing. Genome Biol 2013; 14: 405.
16. Sheridan C: Illumina claims $1,000 genome win. Nat Biotechnol 2014; 32: 115.
17. MIT Technology Review. Available at http://www.technologyreview.com/news/531091/emtech-illumina-says-228000-human-genomes-willbe- sequenced-this-year/; accessed May 18, 2015.
18. de Konig APJ, Gu W, Castoe TA, Batzer MA, Pollock DD: Repetitive elements may comprise over two-thirds of the human genome. Plos One 2012; 7(12): e1002384.
19. Jain M, Fiddes IT, Miga KH, Olsen HE, Paten B, Akeson M: Improved data analysis for the MinION nanopore sequencer. Nat Methods 2015; 12: 351–6.
20. Welter D, MacArthur J, Morales J, et al: The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res 2014; 42: D1001–6.
21. Manolio TA, Collins FS, Cox NJ, et al: Finding the missing heritability of complex diseases. Nature 2009; 461: 747–53.
22. Biesecker LG, Green RC: Diagnostic clinical genome and exome sequencing. N Engl J Med 2014; 370: 2418–25.
23. Yang Y, Muzny DM, Reid JG, et al: Clinical whole-exome sequencing for the diagnosis of Mendelian disorders. N Engl J Med 2013; 369: 1502–11.
24. Bradburne CE, Carruth LM, Lin JS, Sivakumar A, Benson JH, Vogel RA: Implementing genome-informed personalized medicine in the U.S. Air Force Medical Service via the Patient-Centered Precision Care research (PC2-Z) program. Johns Hopkins APL Tech Digest 2013; 31(4): 333–44.
25. Waddington CH: The epigenotype. 1942. Int J Epidemiol 2012; 41: 10–3.
26. Holliday R: The inheritance of epigenetic defects. Science 1987; 238: 163–70.
27. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A: An operational definition of epigenetics. Genes Dev 2009; 23: 781–3.
28. Portela A, Esteller M: Epigenetic modifications and human disease. Nat Biotechnol 2010; 28: 1057–68.
29. Hou L, Zhang X, Wang D, Baccarelli A: Environmental chemical exposures and human epigenetics. Int J Epidemiol 2012; 41: 79–105.
30. Pellegrini M, Ferrari R: Epigenetic analysis: ChIP-chip and ChIP-seq. Methods Mol Biol 2012; 802: 377–87.
31. Schadt EE, Banerjee O, Fang G, et al: Modeling kinetic rate variation in third generation DNA sequencing data to detect putative modifications to DNA bases. Genome Res 2013; 23: 129–41.
32. Venkatesan BM, Bashir R: Nanopore sensors for nucleic acid analysis. Nat Nanotechnol 2011; 6(10): 615–24.
33. Fagerberg L, Hallstrom BM, Oksvold P, et al: Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics 2014; 13: 397–406.
34. Heidecker B, Kittleson MM, Kasper EK, et al: Transcriptomic biomarkers for the accurate diagnosis of myocarditis. Circulation 2011; 123: 1174–84.
35. Brothers JF, Hijazi K, Mascaux C, El-Zein RA, Spitz MR, Spira A: Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era. BMC Med 2013; 11: 168.
36. Zhang L, Xiao H, Zhou H, et al: Development of transcriptomic biomarker signature in human saliva to detect lung cancer. Cel Mol Life Sci 2012; 69: 3341–50.
37. O’Grada CM, Morine MJ, Morris C, et al: PBMCs reflect the immune component of the WAT transcriptome: implications as biomarkers of metabolic health in the postprandial state. Mol Nutr Food Res 2014; 58: 808–20.
38. Connor SC, Hansen MK, Corner A, Smith RF, Ryan TE: Integration of metabolomics and transcriptomics data to aid biomarker discovery in type 2 diabetes. Mol Biosyst 2010; 6: 909–21.
39. Hernandez GE, Mondala TS, Head SR: Assessing a novel roomtemperature RNA storage medium for compatibility in microarray gene expression analysis. BioTechniques 2009; 47: 667–8, 670.
40. Graham DR, Elliott ST, Van Eyk JE: Broad-based proteomic strategies: a practical guide to proteomics and functional screening. J Physiol 2005; 563: 1–9.
41. Parker CE, Borchers CH: Mass spectrometry based biomarker discovery, verification, and validation—quality assurance and control of protein biomarker assays. Mol Oncol 2014; 8: 840–58.
42. Weiss F, van den Berg BH, Planatscher H, Pynn CJ, Joos TO, Poetz O: Catch and measure-mass spectrometry-based immunoassays in biomarker research. Biochim Biophys Acta 2014; 1844: 927–32.
43. Wei J, Ding C, Zhang J, et al: High-throughput absolute quantification of proteins using an improved two-dimensional reversed-phase separation and quantification concatemer (QconCAT) approach. Anal Bioanal Chem 2014; 406: 4183–93.
44. Percy AJ, Simon R, Chambers AG, Borchers CH: Enhanced sensitivity and multiplexing with 2D LC/MRM-MS and labeled standards for deeper and more comprehensive protein quantitation. J Proteomics 2014; 106: 113–24.
45. Yin HR, Zhang L, Xie LQ, et al: Hyperplex-MRM: a hybrid multiple reaction monitoring method using mTRAQ/iTRAQ labeling for multiplex absolute quantification of human colorectal cancer biomarker. J Proteome Res 2013; 12(9): 3912–19.
46. Hutchinson SE, Leveridge MV, Heathcote ML, et al: Enabling lead discovery for histone lysine demethylases by high-throughput RapidFire mass spectrometry. J Biomol Screen 2012; 17: 39–48.
47. Southey BR, Lee JE, Zamdborg L, et al: Comparing label-free quantitative peptidomics approaches to characterize diurnal variation of peptides in the rat suprachiasmatic nucleus. Anal Chem 2014; 86: 443–52.
48. Leichtle AB, Dufour JF, Fiedler GM: Potentials and pitfalls of clinical peptidomics and metabolomics. Swiss Med Wkly 2013; 143: w13801.
49. Geier DA, Kern JK, Garver CR, et al: Biomarkers of environmental toxicity and susceptibility in autism. J Neurol Sci 2009; 280: 101–8.
50. Fahrenholz T, Wolle MM, Kingston HM, et al: Molecular speciated isotope dilution mass spectrometric methods for accurate, reproducibleand direct quantification of reduced, oxidized and total glutathione in biological samples. Anal Chem 2015; 87(2): 1232–40.
51. Patti GJ, Yanes O, Siuzdak G: Innovation: metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 2012; 13: 263–9.
52. Naz S, Vallejo M, Garcia A, Barbas C: Method validation strategies involved in non-targeted metabolomics. J Chromatogr A 2014; 1353: 99–105.
53. Fei F, Bowdish DM, McCarry BE: Comprehensive and simultaneous coverage of lipid and polar metabolites for endogenous cellular metabolomics using HILIC-TOF-MS. Anal Bioanal Chem2014; 406: 3723–33.
54. Callahan DL, De Souza D, Bacic A, Roessner U: Profiling of polar metabolites in biological extracts using diamond hydride-based aqueous normal phase chromatography. J Sep Sci 2009; 32: 2273–80.
55. Knee JM, Rzezniczak TZ, Barsch A, Guo KZ, Merritt TJ: A novel ion pairing LC/MS metabolomics protocol for study of a variety of biologically relevant polar metabolites. J Chromatogr B Analyt Technol Biomed Life Sci 2013; 936: 63–73.
56. Awad H, El-Aneed A: Enantioselectivity of mass spectrometry: challenges and promises. Mass Spectrom Rev 2013; 32: 466–83.
57. Paglia G, Williams JP, Menikarachchi L, et al: Ion mobility derived collision cross sections to support metabolomics applications. Anal Chem 2014; 86: 3985–93.
58. Tsugawa H, Kanazawa M, Ogiwara A, Arita M: MRMPROBS suite for metabolomics using large-scale MRM assays. Bioinformatics 2014; 30(16): 2379–80.
59. Milne SB, Mathews TP, Myers DS, Ivanova PT, Brown HA: Sum of the parts: mass spectrometry-based metabolomics. Biochemistry 2013; 52: 3829–40.
60. Simmler C, Napolitano JG, McAlpine JB, Chen SN, Pauli GF: Universal quantitative NMR analysis of complex natural samples. Curr Opin Biotech 2014; 25: 51–9.
61. Yanes O, Tautenhahn R, Patti GJ, Siuzdak G: Expanding coverage of the metabolome for global metabolite profiling. Anal Chem 2011; 83: 2152–61.
62. Wikoff WR, Kalisak E, Trauger S, Manchester M, Siuzdak G: Response and recovery in the plasma metabolome tracks the acute LCMV-induced immune response. J Proteome Res 2009; 8: 3578–87.
63. Shui G, Guan XL, Low CP, et al: Toward one step analysis of cellular lipidomes using liquid chromatography coupled with mass spectrometry: application to Saccharomyces cerevisiae and Schizosaccharomyces pombe lipidomics. Mol Biosystems 2010; 6: 1008–17.
64. Taguchi K, Fukusaki E, Bamba T: Supercritical fluid chromatography/ mass spectrometry in metabolite analysis. Bioanalysis 2014; 6(12): 1679–89.
65. Hartler J, Tharakan R, Kofeler HC, Graham DR, Thallinger GG: Bioinformatics tools and challenges in structural analysis of lipidomics MS/MS data. Brief Bioinform 2013; 14: 375–90.
66. ATSDR: Interaction profiles for toxic substances. Available at ; accessed December 23, 2014.
67. Malherbe L: T-Cell epitope mapping. Ann Allergy Asthma Immunol 2009; 103(1): 76–9.
68. Blackwell A, Aja S, Zhou W, Graham D, Ronnett G: Multi-Omics Compatible protocols for preparation and extraction of biological samples for wide coverage in untargeted metabolomics experiments. Agilent Technologies, Technical Overviews. 2013. Available at ; accessed January 5, 2015.
69. Taylor CF, Field D, Sansone S-A, Aerts J, Apweiler R, et al. Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project. Nat Biotechnol 2008; 26: 889–96.
70. Kolker E, Ozdemir V, Martens L, et al: Toward more transparent and reproducible omics studies through a common metadata checklist and data publications. OMICS 2014; 18(1): 10–14.
71. Chain PS, Grafham DV, Fulton RS, et al: Genome project standards in a new era of sequencing. Science 2009; 326: 236–7.
72. Ladner JT, Beitzel B, Chain PSG, et al: Standards for sequencing viral genomes in the era of high-throughput sequencing. MBio 2014; 5(3): e01360–14.
73. Green RC, Berg JS, Grody WW, et al: ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013; 15: 565–74.
74. De Souza YG, Greenspan JS: Biobanking past, present and future: responsibilities and benefits. AIDS 2013; 27(3): 303–12.
75. Green RC, Lautenbach D, McGuire AL: GINA, genetic discrimination, and genomic medicine. N Engl J Med 2015; 372: 397–9.